Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine

NCT04406649 is registered in ClinicalTrials.gov with Satsuma Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04406649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04406649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 14, 2020
Completion date
January 16, 2023
Enrollment
482 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

migraine, migraine with aura, migraine without aura